COGSTATE LIMITED (CGS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CGS - COGSTATE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.07
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.965

22 Nov
2024

-0.025

OPEN

$0.99

-2.53%

HIGH

$0.99

85,050

LOW

$0.96

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx4.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx66.3 M
Book Value Per Share xxxxxxxxxxxxxxx35.9
Net Operating Cash Flow xxxxxxxxxxxxxxx10.0 M
Net Profit Margin xxxxxxxxxxxxxxx12.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx14.11 %
Return on Invested Capital xxxxxxxxxxxxxxx14.02 %
Return on Assets xxxxxxxxxxxxxxx9.91 %
Return on Equity xxxxxxxxxxxxxxx14.11 %
Return on Total Capital xxxxxxxxxxxxxxx15.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx9.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx45 M
Price To Book Value xxxxxxxxxxxxxxx3.12

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx2.9 M
Capex % of Sales xxxxxxxxxxxxxxx4.35 %
Cost of Goods Sold xxxxxxxxxxxxxxx48 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

27/08/2024

1

Buy

$1.45

50.26%

FY24 results for Cogstate were in line with Canaccord Genuity's forecasts. The broker remains remain confident in the longer-term outlook given growth in the broad central nervous system (CNS) space and new customer acquisition.

The analyst explains revenue lumpiness from current trial delays and/or cancellations is standard practice for service and technology providers in the clinical trials space.

The Buy rating is unchanged, and the target falls to $1.45 from $1.80 after the broker moderates near-term revenue expectations based on the current contracted revenue figure.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 4.37 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.28 cents.
Access Extra Coverage Research History >

CGS STOCK CHART

FNArena News on CGS

1
Australian Broker Call *Extra* Edition – Aug 28, 2024

Aug 28 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 31, 2023

Oct 31 2023 - Daily Market Reports
3
FNArena Corporate Results Monitor – 24-08-2023

Aug 24 2023 - Australia
4
Australian Broker Call *Extra* Edition – May 16, 2023

May 16 2023 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 12-05-23

May 15 2023 - Weekly Reports

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps